期刊
NEUROSURGERY CLINICS OF NORTH AMERICA
卷 23, 期 2, 页码 289-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nec.2012.01.004
关键词
Gliadel; BCNU wafers; Local chemotherapy; Glioma
The 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; carmustine) polymer wafer (Gliadel) was developed for use in malignant glioma to deliver higher doses of chemotherapy directly to tumor tissue while bypassing systemic side effects. Phase III clinical trials for patients with newly diagnosed malignant gliomas demonstrated a small, but statistically significant, improvement in survival. However, the rate of complications, including an increase in cerebrospinal fluid leaks and intracranial hypertension, has limited their use. This article reviews the current data for use of BCNU wafers in malignant gliomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据